Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (CMPS)
NASDAQ:CMPS
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.49Last Year’s EPS
-0.55Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -19.46%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call highlights COMPASS Pathways' solid financial position and progress in clinical trials, particularly for TRD and PTSD, with strategic collaborations enhancing market insights. However, increased net loss and operational costs present financial challenges.Company Guidance
In the recent COMPASS Pathways' investor call, several key metrics were highlighted regarding their financial and clinical progress. For the fiscal year 2024, the company reported a net loss of $155.1 million, or $2.3 per share, compared to the previous year's net loss of $118.5 million. Research and development expenses rose to $119 million from $87.5 million in 2023, while general and administrative expenses increased to $59.2 million. The company ended 2024 with $165.1 million in cash and cash equivalents and secured an additional $140 million in January through financing, providing runway through the second half of 2026. The upcoming COMP360 trials in treatment-resistant depression (TRD) have reached over 90% recruitment, and critical efficacy results, including MADRS effect size, p-value, and confidence intervals, are anticipated in the second quarter of 2025. The company also plans to resume development of COMP360 for PTSD, aiming to maximize success probability and expedite availability to patients.Strong Financial Position
COMPASS Pathways completed a financing round in January, resulting in approximately $140 million in net proceeds. Combined with the $165.1 million in cash at year-end 2024, this provides substantial runway to fund operations through the 26-week data readout from the COMP006 study expected in the second half of 2026.
Progress in Clinical Trials
The company has recruited over 90% of patients for the COMP005 trial, with top line results expected in the next quarter. The COMP006 trial is also enrolling well, with results expected in the second half of 2026.
Expansion into PTSD Treatment
Following recent financing, COMPASS Pathways is resuming development of COMP360 for PTSD, building on encouraging results from a Phase 2a study.
Strategic Collaborations for Market Insights
Collaborations with healthcare delivery organizations are providing insights into various care settings, aiding strategic planning for potential launch and scale-up.
---
CMPS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CMPS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $3.70 | $3.92 | +5.95% |
| Oct 31, 2024 | $6.19 | $4.76 | -23.10% |
| Aug 01, 2024 | $7.63 | $6.88 | -9.83% |
| May 08, 2024 | $8.54 | $8.50 | -0.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does COMPASS Pathways (CMPS) report earnings?
COMPASS Pathways (CMPS) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is COMPASS Pathways (CMPS) earnings time?
COMPASS Pathways (CMPS) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CMPS EPS forecast?
CMPS EPS forecast for the fiscal quarter 2025 (Q1) is -0.49.
---